Edition:
United States

Akorn Inc (AKRX.O)

AKRX.O on Nasdaq

33.53USD
23 Jun 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$33.53
Open
$33.52
Day's High
$33.57
Day's Low
$33.48
Volume
2,472,890
Avg. Vol
3,507,327
52-wk High
$35.40
52-wk Low
$17.61

Select another date:

Tue, Apr 25 2017

Photo

Fresenius picks up M&A pace with Akorn, Merck KGaA deals

FRANKFURT German healthcare group Fresenius SE & Co KGaA has stepped up its dealmaking, agreeing to buy U.S. generic drugmaker Akorn Inc for $4.75 billion (4.37 billion euros) and the biosimilars arm of Germany's Merck KGaA.

UPDATE 2-Fresenius picks up M&A pace with Akorn, Merck KGaA deals

* Fresenius shares up almost 1 percent (Adds advisers, shares, background, CEO, analyst comments)

BRIEF-Akorn deal to pay Fresenius Kabi AG termination fee of $129 mln under specified circumstances

* Akorn - deal with Fresenius Kabi provides under specified circumstances, co to be required to pay Fresenius Kabi AG termination fee of $129 million Source text: (http://bit.ly/2oEMWQV) Further company coverage:

Fresenius snaps up Akorn, Merck KGaA's biosimilars in separate deals

FRANKFURT, April 24 Acquisitive German healthcare conglomerate Fresenius SE & Co KGaA revved up its deals pace by acquiring U.S. generic drugmaker Akorn Inc for $4.75 billion (4.37 billion euros), and in a separate deal, the biosimilars unit of German peer Merck KGaA .

Exclusive: Fresenius nears deal to acquire Akorn - sources

German healthcare conglomerate Fresenius SE & Co KGaA is close to acquiring generic drugmaker Akorn Inc in an all-cash deal valuing the company at more than $4 billion, people familiar with the matter said on Monday.

Akorn hit with $20.5 million verdict over failure to warn

Generic drugmaker Akorn Inc must pay $20.5 million in a lawsuit by a Georgia teacher who accused the company of failing to warn that one of its products would react adversely with another medication she was already taking, a state court jury has ruled.

Germany's Fresenius in talks to buy generic drugmaker Akorn

German healthcare group Fresenius SE & Co KGaA said on Friday that it was in talks with the generic drugmaker Akorn Inc for a potential takeover.

UPDATE 3-Germany's Fresenius in talks to buy generic drugmaker Akorn

April 7 German healthcare group Fresenius SE & Co KGaA said on Friday that it was in talks with the generic drugmaker Akorn Inc for a potential takeover.

BRIEF-Akorn confirms discussions with Fresenius Kabi

* Akorn Inc- Akorn is currently in discussions with Fresenius Kabi, a subsidiary of Fresenius SE & Co. KGaA concerning a potential acquisition of Akorn Source text for Eikon: Further company coverage:

Germany's Fresenius weighing bid for generic drugmaker Akorn -Bbg

April 7 German healthcare group Fresenius SE & Co KGaA is weighing a bid for generic drugmaker Akorn Inc, Bloomberg reported on Friday, citing people familiar with the matter.

Select another date:

More From Around the Web